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ABSTRACT
The incidence of refractory acute myeloid leukemia
(AML) is on the increase due in part to an aging popula-
tion that fails to respond to traditional therapies. High
throughput genomic analysis promises better diagnosis,
prognosis, and therapeutic intervention based on improved
patient stratification. Relevant preclinical models are
urgently required to advance drug development in this
area. The collaborating oncogenes, HOXA9 and MEIS1,
are frequently co-overexpressed in cytogenetically normal
AML (CN-AML), and a conditional transplantation mouse
model was developed that demonstrated oncogene depend-
ency and expression levels comparable to CN-AML
patients. Integration of gene signatures obtained from the
mouse model and a cohort of CN-AML patients using stat-
istically significant connectivity map analysis identified
Entinostat as a drug with the potential to alter the leuke-
mic condition toward the normal state. Ex vivo treatment
of leukemic cells, but not age-matched normal bone mar-
row controls, with Entinostat validated the gene signature
and resulted in reduced viability in liquid culture,
impaired colony formation, and loss of the leukemia ini-
tiating cell. Furthermore, in vivo treatment with Entino-
stat resulted in prolonged survival of leukemic mice. This
study demonstrates that the HDAC inhibitor Entinostat
inhibits disease maintenance and prolongs survival in a
clinically relevant murine model of cytogenetically normal
AML. STEM CELLS 2013;31:1434–1445
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INTRODUCTION
Large-scale analysis of the leukemic genome and transcriptome
has unearthed abnormalities in key cellular and molecular path-
ways. Microarray-based gene expression profiling, in particular,
has identified novel disease subclasses at diagnosis [1–5]. The
ability to sequence complete genomes at high resolution has
resulted in the generation of disease-specific data silos. How-
ever, the true value of such technologies to the fundamental
understanding of the disease state and integration into clinical
practice has yet to be fully realized [6]. Connectivity mapping
(cMap) is an experimental bioinformatics approach to identify
and map underlying genetic differences in disease states to
toxicology profiles of small-molecule therapeutics [7]. A recent
adaptation of this method that incorporates a robust statistical
significance and perturbation algorithm, termed statistically sig-
nificant connectivity map (sscMap), provides a platform to in-
terrogate relevant models of disease and integrate expression
profiling with treatment response to rationally designed thera-
peutics for redeployment [8, 9].
Several leukemia-associated gene rearrangements have
been recapitulated in genetically engineered mouse models,
some of which have been used successfully to monitor
response to therapy and provide insights into chemosensitivity
and chemoresistance [10]. Similarly, transduction/transplanta-
tion studies have been widely used to recapitulate deregulated
oncogene expression in the leukemia setting and provide a
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basis for functional studies. The relatively long disease laten-
cies observed in some models, for example, Mixed-Lineage
Leukemia-Eleven Nineteen Leukemia (MLL-ENL) and AML1
suggest the need for additional genetic interactions to obtain ro-
bust transplantable models more amenable to therapy-related
studies [11, 12]. Transduction and transplantation of hemato-
poietic stem/progenitor cells with combined oncogenic compo-
nents such as BCR/ABL and AML1, into syngeneic recipients,
results in aggressive and transplantable leukemia [13].
Homeodomain (HD) containing proteins regulate develop-
mental processes including hematopoiesis. A subset with an
atypical HD defined by a three-amino-loop-extension motif
(TALE) form complexes with proteins encoded by the clus-
tered class I homeobox (HOX) genes. An established body of
evidence supports a role for HOX and TALE proteins in
leukemogenesis (reviewed by Argiropoulos and Humphries
[14]). In particular, altered expression of HOXA9 has been
observed in a significant proportion of both human acute mye-
loid leukemia (AML) and acute lymphoid leukemia (ALL) and
reported as the most consistent indicator of poor prognosis in
refractory AML [15–17]. The frequent co-overexpression of
HOXA9 and MEIS1, particularly in leukemias harboring MLL-
rearrangements [18, 19], suggests a vital genetic interaction
between the cofactors, which may be required for leukemia
maintenance in a context-dependent manner [20–23]. Notably,
expression of HOXA9 and MEIS1 is also associated with cyto-
genetically normal AML (CN-AML) where no major genetic
aberrations have been identified [24]. Direct co-overexpression
of HOXA9 and MEIS1 results in an aggressive, transplantable,
and tractable myeloid leukemia in mouse models with a
cytogenetically normal genetic background [25].
A conditional loxP-HOXA9-ires-MEIS1-loxP mouse model
of leukemia (A9M-L2) phenotypically comparable to similar
reported models [26] and with levels of the oncogenes compa-
rable to CN-AML patient samples was developed. Gene sig-
natures obtained from A9M-L2 and CN-AML patient samples
were submitted to the sscMap platform to identify potential
connections with small molecule inhibitors. Of particular
note, three of five of the top candidate small molecule inhibi-
tors identified were identical for the human and mouse condi-
tions. One of these molecules, Entinostat (MS-275,
SNDX275) was selected for further study. Treatment of pri-
mary leukemic cells with Entinostat resulted in reduced cell
viability, impaired colony forming potential, and loss of leu-
kemia maintenance in the murine model. Furthermore, a sin-
gle treatment of Entinostat to leukemic mice in vivo resulted
in extension in survival compared to vehicle treatment.
Together these data support a proof-of-principle that inte-
gration of focused gene expression profiling with in silico
screening using the sscMap platform enables identification of
small molecule inhibitors of leukemia maintenance. In addi-
tion the HOXA9-ires-MEIS1 murine model recapitulates the
human CN-AML phenotype at the molecular level and may
provide a basis for proof-of-concept studies to predict future
therapeutic approaches to treatment of this leukemia subtype.
MATERIALS AND METHODS
Patient Samples and Data
AML samples were obtained at diagnosis. All studies adhered to
the tenets of the Declaration of Helsinki, had ethical committee
approval, and all samples were collected with informed consent
and anonymized. Mononuclear cells were purified using Ficoll-
Paque (GE Healthcare BioSciences AB, Uppsala, Sweden, http://
www.gelifesciences.com) gradient centrifugation. Expression pro-
files were generated from human genome expression arrays (HG-
U133A or HG-U133 Plus 2.0: Affymetrix, Santa Clara, CA,
http://www.affymetrix.com) for nonleukemic (MILE Class 18, n
¼ 74) and intermediate risk (MILE Class 13, n ¼ 351) excluding
patients with 11q23 abnormalities as classified (NCBI Gene
Expression Omnibus Accession number: GSE13204) [27].
Animals
Congenic donor CD45.1þ (C57Bl6/Pep3b or C57Bl/6-Ly5.1) and
recipient CD45.2þ (C57Bl/6J) mice were bred and maintained in
specific pathogen-free facilities (IRIC or BRU-QUB) under guide-
lines of both the Canadian Council on Animal Care (CCAC) and
UK Animals (Scientific Procedures) Act 1986. Experimental pro-
cedures were approved by the Comite de Deontologie de
l’Experimentation sur les Animaux de l’Universite de Montreal
and the Ethical Review Committee for Animal Research, Queen’s
University Belfast.
Retroviral Infection and Transplantation
of Hematopoietic Cells
The loxP-HOXA9-ires-MEIS1-loxP-Neo (A9M-L2) vector was
constructed by polymerase chain reaction (PCR) cloning (details
available on request), and the construct was subcloned into the
XhoI/BamHI site of the murine stem cell proviral vector (MSCV).
All constructs were verified by DNA sequencing. For MSCV-Cre-
GFP, the XhoI/MluI fragment (1,031 bp) of pBluescript-Cre
(kindly provided by Dr. Keith Humphries) was blunt ended and
subcloned into the HpaI site of the MSCV-GFP vector. Generation
of vesicular stomatitis virus-pseudotyped retroviruses, infection of
hematopoietic cells, and transplantation into mice were performed
as described [28]. Recipient mice were sublethally (650–850 cGy)
or lethally (1,300 cGy) irradiated prior to transplantation with bone
marrow (BM) or fetal liver (FL) cells isolated at 14.5 dpc. Ex vivo
exposure to control GFP or Cre-GFP recombinant retroviruses was
limited to 48 hours prior to transplantation.
DNA Analyses
High molecular weight DNA was obtained from hematopoietic
tissues, and Southern blot analysis was performed as previously
described [29]. The probe used was a SalI and MluI fragment of
the neomycin gene (852 bp).
Leukemia morphology, Immunophenotype, and
Flow Cytometry
Tissue infiltration, morphology, and flow cytometry analyses were
performed as described [28]. Allophycocyanin (APC)-conjugated
CD11b (BD Pharmingen, San Jose, CA, San Diego, http://
www.bdbiosciences.com/index[lowen]us.shtml), Fluorescein iso-
thiocyanate (FITC)-conjugated TER119, Phycoerythrin (PE)-con-
jugated CD150, and APC-conjugated CD48 (eBiosciences, San
Diego, CA) antibodies were used for immunophenotyping. APC-
conjugated CD45.1 antibody and PE-conjugated CD45.2 antibody
(eBiosciences, http://www.ebioscience.com) were used for repopu-
lation and PE-conjugated CD45.1 antibody (Southern Biotech, Ala-
bama) for homing assays. All data were acquired and analyzed
using an LSRII cytometer and FACSDiva 6.1.2 (BD Pharmingen)
or FlowJo 7.6.5 software (TreeStar Inc., Ashland, OR, http://
www.treestar.com). Tissues were treated with Modified Wright’s
stain and images were captured at 20 objective. Images were cap-
tured using an inverted microscope (CKX41) with attached digital
camera (E620) both Olympus, Southend-on-Sea, UK.
Gene Expression Profiling
Total BM was collected by flushing femurs and tibias of age-
matched control or A9M-L2 mice, and total RNA was isolated
and cDNAs were generated as previously described [30]. For
stem cell pluripotency and immune response profiling, cDNA
samples were prepared with TaqMan Universal PCR mix and
(200 ng/100 lL) loaded into each of the eight ports on the
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predesigned 384 well cards of the TaqMan Gene Expression
Array. Quantitative reverse transcriptase PCR (qRT-PCR) was
performed as per the manufacturer protocol and analyzed using
the 7900 HT Sequence Detection System, all ABI (Applied
Biosystems, Foster City, CA, Foster City, CA, http://www.ap-
pliedbiosystems.com). 18S rRNA was used as the endogenous
control calibrator for subsequent analysis. For analysis by the
Biotrove transcription factor panel array, RNA was converted to
cDNA with High capacity cDNA RT kit (ABI #4368813) and
used at 108 ng/lL of cDNA for 32 cycles of qRT-PCR. Expres-
sion data were filtered by Ct confidence [mt]300 and presence or
absence of a symmetrical peak in a melting curve analysis. An
arbitrary Ct value of 26 was used as the cut-off between
expressed and nonexpressed genes. The combined expression of
peptidylprolyl isomerase A (Ppia) and b-Actin was used as the
endogenous control calibrators for subsequent analysis.
A subset of candidate genes identified from the array plat-
forms were used for validation by individual SYBR Green 1
based qRT-PCR assays. For these assays, the original experimen-
tal cDNA was used and validated primer sets were obtained from
PrimerBank (http://pga.mgh.harvard.edu/primerbank/) using the
relevant gene accession numbers.
Bioinformatics and cMap
Connections between drug-induced gene expression profiles and
gene signatures representing the AML disease or normal BM
(NBM) state were obtained by sscMap [8] to 1,309 reference pro-
files obtained from the BROAD Institute cMap database. For the
mouse model, a list of all genes with a minimum 6 fourfold
change in expression between AML and NBM (n ¼ 5 per group)
were ranked and converted to Affymetrix HG-U133A probeset
IDs where possible. Differentially expressed genes were identified
using a t test. A gene signature with 47 Affymetrix probeset IDs,
representing 30 individual genes, returned significant connections
to drugs at 1% false discovery rate (FDR ¼ 0.01). For the MILE
study, the Affymetrix MAS5 value on the log scale was used as a
measure of gene expression level. Class 13 (CN-AML plus fewer
than three structural abnormalities, excluding 11q23, n ¼ 351)
versus Class 18 (nonleukemia and healthy BM, n ¼ 74) compari-
son was carried out using two-sample t test to identify signifi-
cantly differentially expressed genes. Following the same FDR
criterion as above, a gene signature with 24 Affymetrix Probeset
IDs, representing 21 individual genes, was constructed. The two
gene lists were submitted to sscMap for connectivity mapping. A
perturbation stability score of robustness was calculated for each
significant connection (1 ¼ robust, 0 ¼ weak). Candidate drugs
were prioritized, based on combined rational application of the
connection, statistical significance and perturbation score.
Ex Vivo Entinostat Treatment
Primary AML samples were rapidly thawed and cultured for up
to 72 hours in roswell park memorial institute (RPMI) 10% fetal
calf serum (FCS) (Life Technologies, Paisley, U.K. http://www.li-
fetech.com) containing Entinostat, or the pan-histone deacetylase
inhibitor Panobinostat (both Selleckchem, Munich, Germany,
http://www.selleckchem.com). To reduce the potential for nonspe-
cific effects, the inhibitors were used at the lowest IC50 doses
reported to result in effective histone deacetylase (HDAC)-1 and
pan-HDAC inhibition, [31, 32] or Dimethyl Sulfoxide (DMSO;
vehicle control). Cell viability was quantified by evaluation of
ATP levels using CellTiter-Glo (Promega, Madison, WI, http://
www.promega.com). Primary A9M-L2 or mouse NBM cells were
rapidly thawed and allowed to recover in expansion media, as
previously described [26]. Recovered mouse cells or primary
AML samples were treated in culture with Entinostat or Panobi-
nostat at the stated concentrations or DMSO (vehicle control,
final concentration 0.01%) for 24 hours, then plated in MethoCult
GF M3434 media (Stem Cell Technologies, Vancouver, BC, Can-
ada, http://www.stemcell.com) or directly transplanted into irradi-
ated recipient mice at the stated concentration and dosage. Meth-
ylcellulose cultures were maintained in a humidified incubator at
37C with 5% CO2 for up to 10 days when colony formation,
colony counts, and photo images were captured and analyzed.
Colony staining with 1 mg/mL p-iodonitrotetrazolium violet
(INT, Sigma-Aldrich, Gillingham, U.K., http://www.sigmaal-
drich.com) for 16 hours enabled visualization of colonies and
determination of metabolic activity. Images were captured at the
stated magnification using an inverted microscope (CKX41) with
attached digital camera (E620) both Olympus. Recipient mice
were followed until disease development or up to 80 days at
which point necropsy was performed and hematopoietic tissue
was examined.
In Vivo Entinostat Treatment of Leukemic Mice
Sublethally irradiated (850 cGy) recipient mice (CD45.2þ) were
transplanted with A9M-L2-derived BM cells (1  106) to regen-
erate leukemia. After 14 days of transplantation, leukemia harbor-
ing mice were treated intravenously with vehicle control or a
bolus of Entinostat (30 mg/kg) previously shown to be within the
maximal tolerated dose range [33, 34]. Mice were monitored until
disease development, necropsied and hematopoietic tissue was
examined.
Protein Analysis
Total cell lysates were prepared after incubation of leukemic cells
(primary A9M-L2 or A9M cell line) in vehicle (DMSO) or his-
tone deacetylase class I inhibitor (HDACi) containing media at
the indicated dosage and time, using an SDS extraction protocol
(Cell Signaling Technology, Danvers, MA, http://www.cellsignal.-
com). Proteins were separated by SDS-PAGE and probed with
the following antibodies: caspase 3 (1:1,000; Cell Signaling Tech-
nology); p21CIP/WAF (1:200; Santa Cruz Biotechnology, Santa
Cruz, CA, http://www.scbt.com); Acetyl-Histone H3 (Lys9;
C5B11), Histone H3 (D1H2), Acetyl-Histone H4 (Lys8), Histone
H4 (L64C1) (1:1,000; Acetyl-Histone Antibody Sampler Kit
#9933, Cell Signaling Technology). Equal loading was assessed
using a mouse monoclonal b-actin primary antibody (1:5,000;
Sigma-Aldrich, St Louis, MO). Blots were developed with a
chemiluminescence detection system (Immobilon Western Chemi-
luminescent horseradish peroxidase (HRP) Substrate; MerkMilli-
pore, Billerica, MA, http://www.millipore.com), exposed to X-ray
film (SLS/MOL 7016, Analab, Lisburn, U.K.) for up to 20
minutes, developed, and images were obtained using an Auto-
Chemi Imaging system (UVP, Upland, CA). Densitometry was
performed using an Auto-Chemi Imaging system (UVP, Upland,
CA) and LabWorks software (LabWorks software, Version 4.6,
UVP, Upland, CA).
Chromatin Immunoprecipitation and
qRT-PCR Analysis
A9M or A9M-L2 cells were cultured at a density of 0.625  106
per mL in maintenance media supplemented with 300 nM Entino-
stat or vehicle control. Cells were crosslinked for 10 minutes at
37C with 1.5% (w/v) formaldehyde after the appropriate treatment
time. Chromatin was isolated, sonicated, and immunoprecipited as
per manufacturer protocols using the Acetyl-Histone H4 Immuno-
precipitation (ChIP) Assay Kit (Millipore, Billerica, MA). qRT-
PCR for ChIP enrichment was as per the manufacturer protocol
using SYBR Green PCR mastermix (Roche Diagnostics Limited,
West Sussex, U.K., http://www.roche-applied-science.com) and an-
alyzed by the ABI PRISM 7500 system (Applied Biosystems).
Control immunoprecipitations were performed by substituting Ace-
tyl-Histone H4 antibody with negative control rabbit immunoglo-
bulins (Dako, Cambridgeshire, U.K., http://www.dako.com). Fold
enrichment was determined by normalizing threshold cycle values
of ChIP samples against sonicated whole cell DNA extract, set at
a value of 1. Primer sequences for the p21CIP/WAF ChIP assays
were (50-TCAAAACGACCTGAATGCCTA-30 and 50-GTACAGT-
TAGAGC TGAGTGAGT-30). The A9M cell line and A9M-L2 pri-
mary leukemia cells were also treated with vehicle (DMSO) or
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300 nM Entinostat for 8, 16, or 24 hours. Gene expression was
assessed by qRT-PCR using SYBR Green PCR mastermix and
p21CIP/WAF primers (50-CACAGGCACCATGTCCA ATC-30, 50-
GAA ATCTGTCAGGCTGGTCT-30).
Statistical Analysis
ANOVA of microarray experiments was implemented using
Partek Genomics Suite and ANOVA or Student’s t tests were
performed by GraphPad Prism software (GraphPad software,
Version 5.0, LA Jolla, CA) or SPSS software package (IBM,
Portsmouth, U.K.).
RESULTS
Generation and Functional Validation of the
A9M-L2 CN-AML Model
Retroviral transduction of HOXA9-ires-MEIS1 (A9M) into BM
or FL hematopoietic cells has previously been demonstrated to
give rise to aggressive leukemias in mice [26]. To investigate
the requirement of these collaborating oncogenes in leukemia
maintenance, we exploited the Cre-Lox system to generate a
conditional clonal A9M leukemia (A9M-L2). A serial limiting
dilution transplantation model was designed (Fig. 1A) and
Southern blot analysis of digested genomic DNA from hemato-
poietic tissue indicated low integration and clonality as demon-
strated by a small number of EcoRI digested fragments and
equivalent banding patterns in all mice and all tissues (Fig.
1B). The leukemia latency, gross morphology (Fig. 1C), immu-
nophenotype (Fig. 1D; supporting information Fig. S1), and tis-
sue infiltration were consistent with previous studies [26]. Ret-
roviral transduction of the A9M-L2 leukemia cells with Cre-
GFP followed by cell sorting, to isolate the transduced
(CreþGFPþ) cells, resulted in a population of cells (Crehi/
GFPhi) in which the HOXA9-ires-MEIS1 provirus was deleted
(95%) as determined by Southern blot analysis (Fig. 1E), and
a population of cells in which the level of exposure to Cre was
reduced (Crelo/GFPlo) resulting in 50% retention of the trans-
genes (Fig. 1E; supporting information Fig. S2). The latency of
leukemia development in recipients of control GFPþ or Crelo/
GFPlo A9M-L2 cells was comparable (30 6 3 days, Fig. 1F)
suggesting that the remaining A9M-L2 cells were sufficient to
regenerate leukemia. In contrast, recipients of Crehi/GFPhi
A9M-L2 cells in which the transduced HOXA9 and MEIS1
transgenes were effectively deleted, resulting in reduced activ-
ity of clonogenic progenitors, altered cell growth and gene
expression (supporting information Fig. S2), remained healthy,
without any overt signs of disease, during the 150-day observa-
tion period (Fig. 1F), indicating that expansion of the leukemic
cell population depended on continuous overexpression of
HOXA9 and MEIS1.
qRT-PCR analysis demonstrated that the clonal mouse
leukemia expressed HOXA9 and MEIS1 above the levels
determined for either normal nonmanipulated mice or human
AML with favorable prognostic outcome, but within the
range determined for AML with intermediate or adverse
prognosis (supporting information Fig. S3). Therefore, com-
bined low viral titers, in vivo limiting dilution, and clonal
selection generated a mouse model of induced leukemia char-
acterized by expression levels of HOXA9 and MEIS1 compa-
rable to those detected in primary human leukemias. This
represented an appropriate model to search for inhibitors of
HOXA9/MEIS1-associated leukemia maintenance and/or
expansion.
A9M-L2 Model Is Associated with Reduced
Gene Expression
Overexpression of HOXA9 and MEIS1 results in an AML
phenotype. A focus on the associated biology underlying the
disease was taken with respect to quantifying molecular signa-
tures. Since HOX and TALE proteins are transcription factors
that work within networks and affect progenitor/stem cell
function, the Biotrove transcription factor panel and the ABI
TaqMan pluripotent stem cell gene expression array were
used to quantify gene expression levels. In addition, a Taq-
Man immune response array was used to quantify expression
levels and contribution of immunoregulatory gene networks to
the general AML-associated gene signature. In total, 817 indi-
vidual qRT-PCR assays were examined in duplicate for bio-
logical replicates (up to n ¼ 5) from age-matched normal
control or A9M-L2 leukemia BM. A stringent fourfold differ-
ence in expression (equivalent to DDCt ¼ 62) was used as a
cut-off to identify robustly increased or decreased expression
of candidate genes. Using this criterion, 14% (114/817) of the
genes examined demonstrated differential expression between
the normal and leukemic states (supporting information Table
S1). Of the differentially expressed genes, 83% (95/114) dem-
onstrated reduced expression and only 17% (19/114) demon-
strated increased expression in the leukemic state compared to
normal controls (Fig. 2A–2C). A cohort of candidate genes
from the array datasets was validated by individual qRT-PCR
assays, 87% of which showed similar trends in differential
expression (supporting information Fig. S4). Perhaps not sur-
prisingly, HOXA9 and MEIS1 showed the most significant
fold change in expression in A9M-L2 cells (161- and 248-
fold, respectively, p [lt] .05) when compared to NBM, further
validating both the model and the array platform approach.
A9M-L2 Candidate Genes Associate with
Key Molecular Pathways
Submission of the A9M-L2 signature (n ¼ 114 genes) to the
gene ontology (GO) platform GOEAST and DAVID data-
bases identified cell proliferation and transcription factor
activities among the highest ranking biological processes sig-
nificantly affected in the mouse model of leukemia develop-
ment. In addition to transcriptional regulation and immune
responses, submission of the gene list to either the DAVID
analysis platform (supporting information Table S2a, upper
panel) or the GOEAST platform (supporting information Ta-
ble S3) identified enrichment for genes associated with cell
proliferation, activation, and apoptosis. Convincingly, both
platforms identified similar subsets of genes including cyto-
kines and chemokines, E2F transcription families, and cluster
of differentiation markers as being associated with key proc-
esses (supporting information Table S2b). While GOEAST
was able to identify similar ontologies to DAVID bioinfor-
matics analysis, it was unable to assess pathway perturbation.
The leukemic gene signature was therefore compared to the
Kyoto Encyclopedia of Genes and Genomes using the
DAVID software database. Key biological pathways involving
cytokine signaling and adhesion were significantly enriched
within the gene signature, and ‘‘Hematopoietic Lineage’’ and
‘‘Pathways in Cancer’’ were highlighted as major associated
processes (supporting information Table S2a, lower panel).
Leukemia Gene Signature sscMap Analysis
To obtain a list of small molecule inhibitors with the potential
to affect the leukemic state, differentially expressed gene signa-
tures (supporting information Table S4) from the mouse model
(n ¼ 47 probesets representing 30 genes) or MILE dataset (n ¼
24 probesets representing 21 genes) were submitted for sscMap
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analysis. In total 133 of 1,309 and 130 of 1,309 (A9M-L2) con-
nections were shown to be statistically significant, that is,
log10 p [mt] 3.15 for the MILE and A9M-L2 datasets, respec-
tively (Fig. 3A). The expected number of false connections ¼ 1
giving an estimated FDR of 0.0075 for the MILE dataset and
0.0077 for the A9M-L2 model dataset, respectively. Application
of a perturbation algorithm to the data whereby each gene iden-
tified from the normal set (condition 1) versus leukemia set
Figure 1. Experimental design and phenotype of conditional leukemia. (A): Schematic representation of the development and experimentation
of a conditional HOXA9-MEIS1 (A9M-L2) mouse model. (B, left panel): Structure of the targeting vector used to generate A9M-L2 leukemias
indicating the location of flanking loxP sites, the size of anticipated fragments following Cre recombination, and restriction enzymes used to
determine integration and clonality. (B, right panel): A representative Southern blot analysis (NeoR probe) of EcoRI digested genomic DNA
obtained from spleen (S), bone marrow (B), or lymph node (L) showing low integration and clonality in three independent A9M-L2 mice. (C):
Identification of blast cells in hematopoietic tissues from necropsied A9M-L2 mice compared to age-matched normal controls. (D): Representa-
tive dot plots (from n ¼ 5) demonstrating levels of surface markers CD11b/Mac-1, CD48, CD150, and Ter-119 analyzed by flow cytometry in
both the A9M-L2 model and age-matched normal control bone marrow. (E): Southern blot analysis (NeoR probe) of NheI digested plasmid (P)
or genomic DNA from A9M-L2 mice demonstrating the presence of DNA bands at the sizes expected for successful Cre-recombination of the
flanked region at 50% compared to control (pMSCV-GFP) and 95% following selection for GFPHi populations. (F): Kaplan-Meir plot of the per-
centage survival of recipient mice receiving either MSCV-GFP treated A9M-L2 cells (No Cre), unsorted MSCV-Cre-GFP treated A9M-L2 cells
(50%), or GFPHi sorted MSCV-Cre-GFP treated A9M-L2 cells (95%); n ¼ 5 per group. Abbreviations: B, bone marrow; GFP, green fluorescent
protein; LDA, limited dilution assay; LTR, long terminal repeat; S, spleen, L, lymph node; Tx, primary transplant.
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(condition 2) was individually removed to test the strength of
the biological connections resulted in reducing the number
of candidate small molecule inhibitors for functional studies
(Table 1). A perturbation score of 1 is indicative of an
extremely strong connection between a particular drug and the
related gene signature, a perturbation score of 0 is indicative of
a weak connection.
A shortlist of five potential therapeutics with high normal-
ized connectivity scores (3.8 to 4.4) and a perturbation
score of 1 (p [lt] .00015) was identified from the MILE signa-
ture. Similar analysis of the A9M-L2 signature demonstrated
connectivity scores of 3.2 to 4.1 (p [lt] .0015). Comparative
analysis identified overlap of three candidate drugs from the
mouse model and patient samples. Exemestane, a steroidal
Figure 2. Differential gene expression in A9M-L2 leukemia. Waterfall plots from quantitative reverse transcriptase polymerase chain reaction
analysis of an array of genes obtained from bone marrow of A9M-L2 mice compared to age-matched normal bone marrow controls (n ¼ 5 per
group in duplicate). Relative changes in expression are displayed as DDCT values corrected for endogenous controls. Only consistent changes in
DDCT values of greater than 62 are presented. Mean values 6 S.E.M are plotted from (A) stem cell pluripotency, (B) immune response, and (C)
transcription factor array platforms. *A subset of array genes were further validated by individual assays (supporting information Fig. S3).
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aromatase inhibitor, registered a robust perturbation stability of
1 for the MILE but a lower score (0.85) for the A9M-L2 gene
signature. Two drugs, namely; TTNPB (tetrahydro-tetramethyl-
naphthalenyl-propenyl benzoic acid) and Entinostat had a
strong biological connection and perturbation score of 1.0 for
both signatures. TTNPB is a retinoic acid agonist shown previ-
ously to exhibit in vivo toxicity in mouse [35]. Entinostat, a
well-tolerated HDACi [33, 34], was therefore selected as a can-
didate drug for further analysis. Another HDACi, Panobinostat,
not in the 1,309 BROAD Institute cMap Reference Profiles
database, was included for comparative analysis.
Validation of sscMap and Entinostat Activity in
A9M-L2 Cells
Short-term Entinostat treatment (24 hours) of A9M-L2 cells
resulted in increased expression of a subset of genes (9/10),
previously identified as being decreased in A9M-L2 cells
compared to controls, and part of the signature originally used
to obtain the sscMap (Fig. 3B). These data validated the
extension of the sscMap from cell lines to the primary leuke-
mia cells. The reported cellular effects of Entinostat, most
notably antiproliferative responses, were functionally
Figure 3. sscMap validation, acetylation of histones, and induction of p21CIP/WAF in Entinostat-treated A9M-L2 cells. (A): A scattergram vol-
cano plot depicting statistically significant connections (SSC) above the 3.15 threshold for –log10 (p value) between 24 MILE data probesets
(upper panel) and 47 A9M-L2 data probesets (lower panel). (B): A bar graph of quantitative reverse transcriptase polymerase chain reaction
(qRT-PCR) values obtained from A9M-L2 leukemias following short-term treatment (24 hours) with Entinostat (300 nM) or vehicle (DMSO)
control (n ¼ 3 per group). Relative expression is displayed as log2 estimated copy number values for HOXA9 and MEIS1 (where Ct 35 ¼ 5 cop-
ies). A subset of the genelist (n ¼ 10) used in the statistically significant connectivity map analysis was examined for differential expression.
(C): Western blot and densitometry analysis of A9M cells showing the effect of treatment on levels of proteins implicated in cell survival and ac-
tivity. Representative data from three independent experiments normalized to b-actin are shown, drug dosages in nM are presented. (D): Bar
graph demonstrating a transient increase in AcH4 binding at the p21CIP/WAF promoter following Entinostat treatment of A9M and A9M-L2 pri-
mary cells as determined by ChIP-qRT-PCR. (E): A bar graph demonstrating transient upregulation of p21CIP/WAF mRNA expression following
Entinostat treatment in A9M and A9M-L2 cells as measured by qRT-PCR analysis. For both (B), (D), and (E) mean values of duplicates 6 SEM
are plotted (n ¼ 3 per group). Significant differences obtained from Student’ t tests denoted by *, p  .05; **, p  .01; ***, p  .001. Abbrevia-
tions: AML, acute myeloid leukemia; DMSO, Dimethyl Sulfoxide; NBM, normal bone marrow; A9M, HOXA9 plus Meis1 primary cell line;
LBM leukemic bone marrow cells from A9M-L2 transplanted mice; ENTO, Entinostat.
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validated by exposing A9M-L2 cells to the drug for up to 48
hours. This treatment resulted in transient hyperacetylation of
Histones H3 and H4 and increased p21CIP/WAF levels. How-
ever, no significant decrease in caspase 3 levels or accumula-
tion of cleaved Poly (ADP-ribose) polymerase (PARP) or cas-
pase 3 products could be detected by Western blot analysis
(Fig. 3C and data not shown). The transient increase in
p21CIP/WAF protein levels following Entinostat treatment was
mimicked by a transient increase in AcH4 occupancy at the
p21CIP/WAF promoter locus (Fig. 3D) and upregulation of
p21CIP/WAF mRNA expression in both A9M and A9M-L2 pri-
mary cells (Fig. 3E). The transient effects may be due to low
metabolic stability of Entinostat or high background of
HDAC activity in A9M leukemic cells.
Three drugs with neutral connectivity scores ([lt] 60.15)
and perturbation values of 0 namely; tamoxifen, thiamine, and
ascorbic acid were examined as negative controls for the
sscMap analysis. None of the treatments resulted in significant
increase in the sscMap gene signature or affected colony for-
mation of A9M-L2 cells (supporting information Fig. S5).
Entinostat Reduces CN-AML Viability and Colony
Formation of A9M-L2
Primary CN-AML patient samples (n ¼ 6) cultured in Panobi-
nostat (7 nM) or Entinostat (300 nM) for up to 72 hours
showed a significant decrease in viability compared to DMSO
(vehicle) controls in liquid culture (Fig. 4A). Methylcellulose
culture demonstrated reduced clonogenic potential and cellu-
larity of colonies produced from Entinostat-treated primary
CN-AML cells compared to Panobinostat or vehicle treated
controls (Fig. 4B), even though treatment of A9M-L2 cells
with 300 nM Entinostat or 7 nM Panobinostat resulted in
comparable increased histone acetylation (supporting informa-
tion Fig. S6). Entinostat treatment of A9M-L2 primary leuke-
mia cells resulted in a similar marked reduction in clonogenic
potential and decreased cellularity compared to Panobinostat,
or vehicle and untreated controls, as demonstrated by INT
staining (Fig. 4C). The observation that Entinostat treatment
did not result in a significant decrease in colony formation of
NBM cells (Fig. 4D) suggests the leukemic cells are particu-
larly Entinostat sensitive.
Entinostat Treatment Prevents A9M-L2 Leukemia
Maintenance and Extends Survival of Leukemic
Mice
The sensitivity of A9M-L2 cells to Entinostat was further demon-
strated in parallel transplantation assays. Aliquots of the ex vivo-
treated and control A9M-L2 cells used for the colony assays
were directly transplanted into recipient mice. A dramatic
decrease in the number of leukemia initiating cells in the Entino-
stat treated cohorts was demonstrated by a complete absence of
overt leukemia during the 80-day observation period (Fig. 5A left
panel), and no leukemic cell infiltrates (Fig. 5A right panel). In
contrast, recipients of untreated, DMSO-treated, or Panobinostat-
treated A9M-L2 cells succumbed to leukemia within approxi-
mately 32 days after transplantation. Entinostat treatment of
NBM cells was well tolerated by recipient mice following trans-
plantation (Fig. 5A left panel) and homing to the spleen or short-
term repopulation in spleen and bone marrow were not markedly
affected compared to controls (supporting information Figs. S7,
S8). Interestingly, both NBM and A9M-L2 cells treated with
Entinostat demonstrated a slight reduction in homing to the bone
marrow (supporting information Fig. S7), which may warrant fur-
ther examination. The low dose of HDACis used in the ex vivo
model treatments, sufficient to activate p21CIP/WAF, did not
induce apoptosis as measured by Annexin V/Propidium Iodide
staining. This phenomenon was, however, observed when drug
concentrations were increased to 1 lM and 25 nM for Entinostat
and Panobinastat, respectively (supporting information Fig. S9).
To determine whether Entinostat was capable of suppress-
ing leukemia development in vivo, recipients of A9M-L2 cells
were treated with a single bolus of Entinostat or vehicle con-
trol on day 14 after leukemia initiation by transplantation and
assessed daily for development of AML. Entinostat treatment
prolonged the survival time of treated leukemic mice by up to
8 days (p ¼ .0140) compared to controls (Fig. 5B left panel),
suggesting that in vivo Entinostat treatment noticeably sup-
pressed and delayed expansion of leukemic cell populations.
Table 1. Candidate small molecule inhibitors (statistically significant connectivity map)
Compound Replicate Raw score p value
Normalized
score Sig. mark
Perturbation
stability
MILE Study Class 18 NBM (n¼ 74) vs. MILE Study Class 13 CN-AML (n¼ 351)
Dinoprostone 4 0.254 1.00E  05 4.359 1 1
Entinostat 2 0.394 2.00E  05 3.871 1 1
Meteneprost 4 0.251 1.40E  04 3.834 1 1
Exemestane 1 0.448 8.00E  05 3.799 1 1
TTNPB 2 0.376 1.20E  04 3.764 1 1
Todralazine 5 0.252 1.00E  05 4.209 1 1
Dequalinium chloride 4 0.350 1.00E  05 4.312 1 1
Guaifenesin 6 0.233 1.00E  05 4.492 1 1
Sulfadiazine 5 0.247 4.515 1 1
Triflusal 3 0.457 1.00E  05 4.670 1 1
Murine model NBM (n¼ 5) vs. A9M-L2 (n¼ 5)
TTNPB 2 0.295 2.00E  05 4.134 1 1
Entinostat 2 0.275 1.20E  04 3.783 1 1
Ampyrone 5 0.177 7.00E  04 3.385 1 0.85
Oligomycin 1 0.281 8.80E  04 3.339 1 0.50
Exemestane 1 0.267 0.00148 3.170 1 0.13
Beclometasone 3 0.152 2.00E  05 4.428 1 1
Sotalol 4 0.185 2.00E  05 4.428 1 1
Mesalazine 5 0.132 1.00E  05 4.449 1 1
Levocabastine 4 0.186 1.00E  05 4.493 1 1
Glafenine 4 0.190 1.00E  05 4.980 1 1
Abbreviations: CN-AML, cytogenetically normal acute myeloid leukemia; NBM, normal bone marrow.
Ramsey, Kettyle, Sharpe et al. 1441
www.StemCells.com
Mice that succumbed to leukemia following the single Entino-
stat treatment presented with a similar phenotype, including
tissue infiltration (Fig. 5B right panel) as vehicle controls.
DISCUSSION
The frequent co-overexpression of HOXA9 and MEIS1 in
AML, particularly in the absence of an underlying genetic
rearrangement, [36, 37] suggests an important role for this
axis above and beyond the well-established link with 11q23
translocations (reviewed by Muntean and Hess [38]). Co-over-
expression of HOXA9 and MEIS1 results in an aggressive and
tractable leukemia in mouse which makes it an attractive
model for molecular and genetic studies [26]. In this work,
we explored the usefulness of a conditional HOXA9/MEIS1-
dependent mouse model to investigate and challenge leukemia
maintenance. A combination of low viral titer and transplanta-
tion with limiting numbers of leukemia initiating cells
resulted in a robust clonal disease that expressed the collabo-
rating oncogenes at levels representative of CN-AML patient
samples. Deletion of the collaborating oncogenes following
exposure to Cre-recombinase resulted in altered colony and
cell growth and loss of leukemia maintenance, defining a
potential therapeutic window. However, therapeutic targeted
gene deletion is currently far removed from the clinical set-
ting and for that reason a drug redeployment strategy was
adopted for candidate drug discovery.
Gene expression analyses of the A9M-L2 leukemia identi-
fied reduced expression (below fourfold) of an array of tran-
scription factor, immune responsive and pluripotent stem cell
associated genes compared to age-matched normal controls.
Only a minor fraction of differentially expressed genes (17%)
demonstrated increased expression above fourfold compared
to NBM controls. The alteration in gene expression obtained
from leukemic bone marrow of A9M-L2 mice reflects the
biology of end-stage disease and is thus unlikely to represent
direct targets of the collaborating oncogenes. However, some
of the genes within the signature, including CD34 and CD28,
have been previously identified as potential targets of
HOXA9/MEIS1 [39].
GO and pathway analysis of the gene signature obtained
from the A9M-L2 model reflected the pathways interrogated
by the specific arrays but furthermore identified regulation of
proliferation, apoptosis, hematopoietic lineage, and cancer path-
ways (among others) as key processes associated with the dif-
ferentially expressed genes. Submission of the CN-AML and
A9M-L2 signatures to sscMap analysis identified robust con-
nectivity between five drugs, in both the clinical and mouse
model samples, associated with promoting condition 1 (normal
bone marrow) over condition 2 (leukemia), thereby indicating
therapeutic potential. Furthermore, three of the drugs identified
(Entinostat, TTNPB, and Exemestane) showed direct overlap
between the CN-AML patients and A9M-L2 model of which
two (Entinostat and TTNPB) demonstrated statistically robust
perturbation scores of 1. One of the compounds (TTNPB) had
previously been shown to have in vivo toxicity in mouse mod-
els [35] and, therefore, Entinostat, a HDACi shown to be well-
tolerated in vivo [33, 34], was selected for further analysis.
Short-term exposure of A9M-L2 cells to low-dose Entino-
stat (300 nM) resulted in acetylation of Histones H3 and H4,
upregulation of the cell cycle inhibitor p21CIP/WAF, and lack
of induction of apoptosis in agreement with previous findings
[40]. Low-dose Entinostat or Panobinostat treatments signifi-
cantly decreased cell viability of primary CN-AML cells in
Figure 4. Entinostat reduces cytogenetically normal acute myeloid leukemia (CN-AML) viability and reduces colony formation of A9M-L2
cells. (A): Bar graph demonstrating viability of primary CN-AML samples following Entinostat (300 nM) or Panobinostat (7 nM) treatment (n ¼
6 per group). Cell viability was assessed as relative fluorescence units obtained from the measurement of ATP concentration at the specified
time. (B): Representative colony images and the total colony forming cell (CFC) content (lower right panel) of the primary CN-AML cell popula-
tions treated with vehicle (DMSO), Panobinostat (7 nM), or Entinostat (300 nM). (C): Colony formation of A9M-L2 cells (n ¼ 3 per group) fol-
lowing control, DMSO, Entinostat (300 nM), or Panobinostat (7 nM) treatment. Left panel, total CFC content of the treated cell populations
(mean 6 SD, n ¼ 3, two experiments); right panel, representative images of colonies. (D): Colony formation of normal bone marrow samples (n
¼ 3 per group) following control, DMSO, or Entinostat (300 nM) treatment. Left panel, total CFC content (mean 6 SD, n ¼ 3, two experi-
ments); right panel, representative images of colonies. Asterisks denote significant differences between the treatments and controls (Student’s t
tests *, p  .05; ** p  .01; *** p  .001). Abbreviation: DMSO, Dimethyl Sulfoxide.
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Figure 5. Entinostat treatment prevents A9M-L2 leukemia maintenance and results in prolonged survival in vivo. Kaplan-Meier plots demon-
strating correlation between treatment regimens and survival in leukemic mice. (A, left panel): A9M-L2 cells were incubated ex vivo for 24 hours
in culture with control media, or in media supplemented with vehicle, or Panobinostat (7 nM), or Entinostat (300 nM) then transplanted (5  105
cells) into sublethally irradiated (850 cGy) mice, which were closely monitored and sacrificed at the first sign of disease. Normal bone marrow
cells treated with Entinostat (300 nM) were transplanted in a control mouse cohort. (A, right panel): Blood smears and tissue touchpreps stained
with Wright-Giemsa showing leukemia infiltration of peripheral blood and solid tissues. (B, left panel): Kaplan-Meier plots demonstrating pro-
longed survival in leukemic (A9M-L2) mice, given an i.v. bolus of Entinostat (30 mg/kg) at day 14 following transplantation, compared to
DMSO controls (n ¼ 5 per group). A control mouse cohort (NBM) was similarly treated and demonstrated no morbidity within the observation
time frame. Significant difference between the treatment and control (Log-rank Mantel-Cox Test; p value ¼ .014). Scale bars ¼ 20 lM. Abbrevi-
ations: DMSO, Dimethyl Sulfoxide; NBM, normal bone marrow.
Figure 6. Proposed mechanism of action for Entinostat in A9M leukemia. Hematopoietic development is in balance, with genetic input
(HOXA9/MEIS1) and epigenetic maintenance, allowing normal differentiation and apoptosis (upper section). Increased HOXA9/MEIS1 input with
potential and associated epigenetic disruption leads to increased proliferation/self-renewal and impaired differentiation. This culminates in leuke-
mia initiation and maintenance. However, maintenance is disrupted by histone deacetylase class I inhibitor (Entinostat) treatment allowing for
epigenetic recovery, reduced proliferation/self-renewal, and restored differentiation which results in loss of leukemia maintenance (lower section).
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liquid culture. Additionally, A9M-L2 leukemia cells treated
with Entinostat demonstrated reduced numbers, size, and me-
tabolism of clonogenic progenitors compared to controls or
Panobinostat-treated cells. The differential cellular effects of
two HDACis used at concentrations that attain comparable
levels of Histone acetylation emphasizes the complexity of
epigenetic regulation and warrants further study.
The decrease in colony formation following Entinostat
treatment correlated with a dramatic reduction in leukemia
initiating cells compared to Panobinostat, control, or vehicle-
treated A9M-L2 cells. This clearly demonstrates that A9M-L2
leukemia cells are sensitive to short-term exposure of Entino-
stat that results in significant depletion and potential purging
of the leukemia-initiating cell possibly by a mechanism of
reduced proliferation/self-renewal and increased differentia-
tion, in part due to the increased activity of p21CIP/WAF (Fig.
6). Association between HOX/TALE activation and epigenetic
drivers such as CBP/P300 recruitment, histone acetylation,
and alternative recruitment of RNA polymerase II has
recently been reported [41, 42]. Together with the data pre-
sented herein, this suggests that collaborating oncogenic dys-
function may result in epigenetic disruption that is potentially
targetable therapeutically. Congruent with this, a single treat-
ment of Entinostat, to developing A9M-L2 leukemia, resulted
in significant extension in survival (8 days) compared to
control or vehicle-treated mouse recipients. The lack of gen-
eral cytotoxicity of Entinostat, as demonstrated by it being
well-tolerated in NBM cells and failing to impair homing or
short-term repopulation, indicates good efficacy which may be
of particular value in combination therapies.
SUMMARY
Together these data show that application of sscMap to genet-
ically defined models can identify small molecule inhibitors
across species that may be clinically relevant. The ex vivo
purging of leukemia maintenance cells and prolonged survival
in vivo supports the potential of Entinostat as a therapeutic
for HOXA9 and MEIS1 overexpressing leukemias. Whether
Entinostat has a direct effect on the proto-oncogenes as
recently suggested [43] or indirectly through other mecha-
nisms, in CN-AML, remains to be determined. Entinostat pro-
longed survival in leukemic mice as a single-agent to a simi-
lar level as that reported for continuous infusion of a potent
small molecule inhibitor [44]. However, epigenetic priming
agents, such as HDACis and hypomethylating molecules will
most likely be more effective as part of a combined therapeu-
tic approach in leukemia and cancer [45–47]. HDACis are
associated with several modes of antitumor activity including
modulation of the immune response [48], cell cycle arrest,
promotion of differentiation, senescence, and apoptosis [46].
Harnessing the beneficial properties of such compounds while
limiting cytotoxic effects will improve their future use partic-
ularly in combination therapy.
Advanced connectivity maps, obtained from in vivo stud-
ies, may accelerate drug development and redeployment of
approved small molecule inhibitors. Therefore, the generation
and treatment of clinically relevant in vivo models becomes
more pressing. This study demonstrates that the HDAC class
I inhibitor Entinostat inhibits disease maintenance and pro-
longs survival in a clinically relevant murine model of cyto-
genetically normal AML.
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